Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesChange in TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Enanta Pharmaceuticals (ENTA) Cash from Operations (2016 - 2025)

Historic Cash from Operations for Enanta Pharmaceuticals (ENTA) over the last 14 years, with Q4 2025 value amounting to -$11.7 million.

  • Enanta Pharmaceuticals' Cash from Operations rose 3036.72% to -$11.7 million in Q4 2025 from the same period last year, while for Dec 2025 it was -$14.2 million, marking a year-over-year increase of 7992.26%. This contributed to the annual value of -$19.3 million for FY2025, which is 7553.2% up from last year.
  • Latest data reveals that Enanta Pharmaceuticals reported Cash from Operations of -$11.7 million as of Q4 2025, which was up 3036.72% from -$6.5 million recorded in Q3 2025.
  • Over the past 5 years, Enanta Pharmaceuticals' Cash from Operations peaked at $17.5 million during Q2 2025, and registered a low of -$35.6 million during Q4 2022.
  • Moreover, its 5-year median value for Cash from Operations was -$16.2 million (2022), whereas its average is -$17.6 million.
  • Per our database at Business Quant, Enanta Pharmaceuticals' Cash from Operations crashed by 55744.21% in 2021 and then surged by 21848.39% in 2025.
  • Over the past 5 years, Enanta Pharmaceuticals' Cash from Operations (Quarter) stood at -$13.3 million in 2021, then crashed by 168.56% to -$35.6 million in 2022, then rose by 29.89% to -$25.0 million in 2023, then skyrocketed by 32.76% to -$16.8 million in 2024, then skyrocketed by 30.37% to -$11.7 million in 2025.
  • Its Cash from Operations was -$11.7 million in Q4 2025, compared to -$6.5 million in Q3 2025 and $17.5 million in Q2 2025.